Mati Therapeutics
Business Services · Texas, United States · <25 Employees
View Company Info for Free
About
Headquarters
101 Colorado St Apt 2409, Austin, Texas, 78701,...Phone Number
(512) 720-1333Website
www.matitherapeutics.comRevenue
<$5 MillionIndustry
Recent News & Media
Highlights
<$5M
Total Funding Amount
<$5M
Most Recent Funding Amount
1
Number of Funding Rounds
Who is Mati Therapeutics
Mati is developing the Evolute® sustained ocular drug delivery platform, which Mati believes has the potential to treat a range of ocular indicatio ns. The platform utilizes a device called a punctal plug, which is easily inserted into a patient's punctum. The device has already been approved to treat dry eye syndrome, but Mati is the first to conduct clinical trials in the U.S. using punctal plugs as an anchoring device for a drug delivery platform. A drug-eluting core is inserted into Mati's proprietary punctal plug, which allows medication to be continuously released into the tear film of the eye over a period of time. Mati believes the Evolute® platform has the potential to become a more reliable alternative to several eye drop therapies, which can be ineffective because many patients are unwilling or unable to adhere to self-administered eye-drop regimens. Mati has completed multiple Phase II clinical trials using the Evolute® platform, including multiple trials in glaucoma, ocular hypertension, and allergy patients. Mati's proprietary punctal plug design has demonstrated excellent lower punctum retention rates of 92% and 96% over a 12-week follow-up period in two separate multi-center U.S. clinical trials.Read more
Mati Therapeutics Org Chart
Is Mati Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Mati Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Mati Therapeutics
Funding: Get notified immidiatlly once Mati Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Mati Therapeutics recently announced quarterly report
Product Launch: Get notified when Mati Therapeutics launches new products
Check out if Mati Therapeutics is spiking on competitors!
Check if Mati Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if Mati Therapeutics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Mati Therapeutics
Find more new buyers
Similar Companies to Mati Therapeutics
Analyze insights from companies similar to Mati Therapeutics and make strategic comparisons based on performance, financial data, growth and unique benchmarks.
- Aldeyra Therapeutics<25
<$5M - Inotek Pharmaceuticals<25<$5M
- Dompé<25<$5M
- Cloudbreak Therapeutics<25<$5M
- Insite Vision<25$5.1M
- Sofpromed31<$5M
- 4P Therapeutics<25<$5M
- Opsis Therapeutics<25<$5M
More similar companies
Mati Therapeutics financials insights
Gather financial insights about Mati Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Mati Therapeutics Employee Growth Rate
View Mati Therapeutics’s full employee growth data
Percentage of growth
1st year Mask
2nd year Mask
Mati Therapeutics Tech Stack
A closer look at the technologies used by Mati Therapeutics
Most Recent Scoops
Sep 26 2023
Promotion
Mati Therapeutics News & Media
MATI THERAPEUTICS ANNOUNCES PROMOTION OF CHRIS MULLER TO CHIEF OPERATING OFFICER
Industry Veteran with over 30 years of ophthalmic experience to guide development and commercial efforts for Mati's expanding late-stage pipeline, including two products about to enter Phase III trials. AUSTIN, Texas, Sept. 26, 2023 /PRNewswire/ -- Mati Therapeutics Inc. ("Mati")...
MATI THERAPEUTICS ANNOUNCES COMPLETION OF MANUFACTURING FACILITY DEDICATED TO GLOBAL PRODUCTION OF ALL PUNCTAL PLUG DELIVERY SYSTEM (PPDS) PRODUCTS
Completion of Facility Enables Initiation of Phase 3 Clinical Trial of Nepafenac in Patients Undergoing Cataract Surgery AUSTIN, Texas, Sept. 12, 2023 /PRNewswire/ -- Mati Therapeutics Inc. ("Mati") announced that it has completed and now occupies a facility dedicated to manufacturing all...Ocular Therapeutix™ Announces Success in Patent Appeal Brought by Mati Therapeutics, Inc.
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the U.S. Court of Appeals for the Federal Circuit in Washington, D.C., invalidated a patent held by Mati Therapeutics, Inc. (Mati) relating to a drug delivery system containing dexamethasone. This decision affirms the judgment made inJCRS Publication of Phase II Nepafenac Clinical Trial With Evolute® Sustained Drug Delivery System Demonstrates Significant Post-Op Pain Reduction in Cataract Surgery Patients
AUSTIN, Texas--(BUSINESS WIRE)--Mati Therapeutics Inc. (“Mati”) announced that a peer reviewed manuscript of a Phase II clinical trial evaluating the safety and efficacy of Nepafenac delivered via Mati’s proprietary Evolute® sustained ocular drug delivery platform has been published in the February Journal of Cataract and Refractive Surgery. The trial is a multi-center, randomized, masked evaluation of Nepafenac vs. placebo in 56 patients undergoing cataract surgery. The primary endpoint was toMati Therapeutics Announces Purchase of Rights From Novelion Therapeutics Inc.
AUSTIN, Texas--(BUSINESS WIRE)--Mati Therapeutics Inc. (“Mati”) announced that it has purchased all rights related to Mati’s Evolute Punctal Plug Delivery System (PPDS) from Novelion Therapeutics Inc. (“Novelion”). This purchase is part of Novelion’s voluntary liquidation process. Mati previously acquired the intellectual property and other assets comprising the PPDS from Novelion (formerly QLT Inc.) in April 2013. As part of the purchase agreement, Mati was obligated to potentially pay Novelio
Read more news
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Frequently Asked Questions Regarding Mati Therapeutics
Mati is developing the Evolute® sustained ocular drug delivery platform, which Mati believes has the potential to treat a range of ocular indications. The platform utilizes a device called a punctal plug, which is easily inserted into a patient's punctum. The device has already been approved to treat dry eye syndrome, but Mati is the first to condu... Read More
